203 related articles for article (PubMed ID: 24315845)
1. Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.
Palmer J; Williams K; Inamoto Y; Chai X; Martin PJ; Tomas LS; Cutler C; Weisdorf D; Kurland BF; Carpenter PA; Pidala J; Pavletic SZ; Wood W; Jacobsohn D; Arai S; Arora M; Jagasia M; Vogelsang GB; Lee SJ
Biol Blood Marrow Transplant; 2014 Mar; 20(3):337-44. PubMed ID: 24315845
[TBL] [Abstract][Full Text] [Related]
2. Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease.
Palmer J; Chai X; Pidala J; Inamoto Y; Martin PJ; Storer B; Pusic I; Flowers ME; Arora M; Pavletic SZ; Lee SJ
Blood; 2016 Jan; 127(1):160-6. PubMed ID: 26527676
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
4. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
5. Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium.
Pidala J; Chai X; Martin P; Inamoto Y; Cutler C; Palmer J; Weisdorf D; Pavletic S; Arora M; Jagasia M; Jacobsohn D; Lee SJ
Biol Blood Marrow Transplant; 2013 Jun; 19(6):967-72. PubMed ID: 23542686
[TBL] [Abstract][Full Text] [Related]
6. National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.
Baird K; Steinberg SM; Grkovic L; Pulanic D; Cowen EW; Mitchell SA; Williams KM; Datiles MB; Bishop R; Bassim CW; Mays JW; Edwards D; Cole K; Avila DN; Taylor T; Urban A; Joe GO; Comis LE; Berger A; Stratton P; Zhang D; Shelhamer JH; Gea-Banacloche JC; Sportes C; Fowler DH; Gress RE; Pavletic SZ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):632-9. PubMed ID: 23340040
[TBL] [Abstract][Full Text] [Related]
7. NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD.
Curtis LM; Grkovic L; Mitchell SA; Steinberg SM; Cowen EW; Datiles MB; Mays J; Bassim C; Joe G; Comis LE; Berger A; Avila D; Taylor T; Pulanic D; Cole K; Baruffaldi J; Fowler DH; Gress RE; Pavletic SZ
Bone Marrow Transplant; 2014 Dec; 49(12):1513-20. PubMed ID: 25153693
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease.
Baumrin E; Baker LX; Byrne M; Martin PJ; Flowers ME; Onstad L; El Jurdi N; Chen H; Beeghly-Fadiel A; Lee SJ; Tkaczyk ER
JAMA Dermatol; 2023 Apr; 159(4):393-402. PubMed ID: 36884224
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.
Sato T; Ichinohe T; Kanda J; Yamashita K; Kondo T; Ishikawa T; Uchiyama T; Takaori-Kondo A
Int J Hematol; 2011 Apr; 93(4):532-541. PubMed ID: 21465116
[TBL] [Abstract][Full Text] [Related]
10. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.
Lee SJ; Wolff D; Kitko C; Koreth J; Inamoto Y; Jagasia M; Pidala J; Olivieri A; Martin PJ; Przepiorka D; Pusic I; Dignan F; Mitchell SA; Lawitschka A; Jacobsohn D; Hall AM; Flowers ME; Schultz KR; Vogelsang G; Pavletic S
Biol Blood Marrow Transplant; 2015 Jun; 21(6):984-99. PubMed ID: 25796139
[TBL] [Abstract][Full Text] [Related]
11. Validation of measurement scales in ocular graft-versus-host disease.
Inamoto Y; Chai X; Kurland BF; Cutler C; Flowers ME; Palmer JM; Carpenter PA; Heffernan MJ; Jacobsohn D; Jagasia MH; Pidala J; Khera N; Vogelsang GB; Weisdorf D; Martin PJ; Pavletic SZ; Lee SJ;
Ophthalmology; 2012 Mar; 119(3):487-93. PubMed ID: 22153706
[TBL] [Abstract][Full Text] [Related]
12. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.
Arai S; Jagasia M; Storer B; Chai X; Pidala J; Cutler C; Arora M; Weisdorf DJ; Flowers ME; Martin PJ; Palmer J; Jacobsohn D; Pavletic SZ; Vogelsang GB; Lee SJ
Blood; 2011 Oct; 118(15):4242-9. PubMed ID: 21791424
[TBL] [Abstract][Full Text] [Related]
13. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality.
Pidala J; Kim J; Anasetti C; Nishihori T; Betts B; Field T; Perkins J
Haematologica; 2011 Nov; 96(11):1678-84. PubMed ID: 21791465
[TBL] [Abstract][Full Text] [Related]
14. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation.
Thepot S; Zhou J; Perrot A; Robin M; Xhaard A; de Latour RP; Ades L; Ribaud P; Petropoulou AD; Porcher R; Socié G
Leukemia; 2010 Nov; 24(11):1852-8. PubMed ID: 20827288
[TBL] [Abstract][Full Text] [Related]
15. Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.
Merkel EC; Mitchell SA; Lee SJ
Biol Blood Marrow Transplant; 2016 Apr; 22(4):752-758. PubMed ID: 26751003
[TBL] [Abstract][Full Text] [Related]
16. Predicting chronic GVHD outcomes: are we there yet?
Jacobsohn DA
Blood; 2016 Jan; 127(1):14-5. PubMed ID: 26744439
[TBL] [Abstract][Full Text] [Related]
17. Analysis of gastrointestinal and hepatic chronic graft-versus-host [corrected] disease manifestations on major outcomes: a chronic graft-versus-host [corrected] disease consortium study.
Pidala J; Chai X; Kurland BF; Inamoto Y; Flowers ME; Palmer J; Khera N; Jagasia M; Cutler C; Arora M; Vogelsang G; Lee SJ
Biol Blood Marrow Transplant; 2013 May; 19(5):784-91. PubMed ID: 23395601
[TBL] [Abstract][Full Text] [Related]
18. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
19. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
20. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria.
Jagasia M; Giglia J; Chinratanalab W; Dixon S; Chen H; Frangoul H; Engelhardt B; Goodman S; Greer J; Kassim A; Morgan D; Ruffner K; Schuening F
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1207-15. PubMed ID: 17889358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
